R M Phillips
Overview
Explore the profile of R M Phillips including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
113
Citations
968
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Suggitt M, Fearnley J, Swaine D, Volpato M, Phillips R, Bibby M, et al.
Teratog Carcinog Mutagen
. 2003 Dec;
Suppl 2:13-29.
PMID: 14691977
In order to determine differences in repair after treatment with DNA damaging agents, normal and cancer cells were selected for analysis of single strand breaks and DNA crosslinks using the...
22.
Basu S, Martin S, Phillips R, Puri R
Lancet
. 2003 Apr;
361(9366):1394.
PMID: 12711507
No abstract available.
23.
Loadman P, Bibby M, Phillips R
Br J Pharmacol
. 2002 Oct;
137(5):701-9.
PMID: 12381684
The bioreductive drug EO9 (3-hydroxy-5-aziridinyl-1-methyl-2[indole-4,7-dione]-prop-beta-en-alpha-ol) has good pharmacodynamic properties in vitro, modest anti-tumour activity in experimental tumour models, but failed to show activity in clinical trials. Understanding the reasons for...
24.
Nicholson K, Phillips R, Shnyder S, Bibby M
Eur J Cancer
. 2001 Dec;
38(1):194-204.
PMID: 11750850
LS 4477 and LS 4559, two of a series of N-acyl-aminoalkyl phenyl ethers, are rationally designed compounds based on the tubulin binder estramustine. This study investigated their mechanism of action...
25.
Knowles H, Phillips R
Anticancer Res
. 2001 Nov;
21(4A):2305-11.
PMID: 11724287
Background: Genes upregulated within the tumour microenvironment represent potential targets for rational drug design. Most studies to date concentrate on the effects of hypoxia, although it is likely many genes...
26.
Choudry G, Stewart P, Double J, Krul M, Naylor B, Flannigan G, et al.
Br J Cancer
. 2001 Nov;
85(8):1137-46.
PMID: 11710826
The indolequinone EO9 demonstrated good preclinical activity but failed to show clinical efficacy against a range of tumours following intravenous drug administration. A significant factor in EO9's failure in the...
27.
Phillips R, Burger A, Fiebig H, Double J
Biochem Pharmacol
. 2001 Nov;
62(10):1371-7.
PMID: 11709197
Pharmacogenetic analysis of polymorphisms in drug metabolizing enzymes is currently generating considerable interest as a means of individualizing patient therapy. Recent studies have suggested that patients that are homozygous for...
28.
Wolska B, Vijayan K, Arteaga G, Konhilas J, Phillips R, Kim R, et al.
J Physiol
. 2001 Nov;
536(Pt 3):863-70.
PMID: 11691878
1. Acidosis in cardiac muscle is associated with a decrease in developed force. We hypothesized that slow skeletal troponin I (ssTnI), which is expressed in neonatal hearts, is responsible for...
29.
Wright C, Addae-Kyereme J, Breen A, Brown J, Cox M, Croft S, et al.
J Med Chem
. 2001 Sep;
44(19):3187-94.
PMID: 11543688
The indoloquinoline alkaloid cryptolepine 1 has potent in vitro antiplasmodial activity, but it is also a DNA intercalator with cytotoxic properties. We have shown that the antiplasmodial mechanism of 1...
30.
Phillips R, Ward T
Anticancer Res
. 2001 Aug;
21(3B):1795-801.
PMID: 11497261
Background: The existence of an acidic extracellular pH (pHe) within solid tumours is regarded as a potential target for drug development. The indolequinone EO9 has a complex mechanism of action...